Shojaei brings over two and a half decades of experience in clinical pharmaceutical development BALTIMORE, MD, October 8, 2021 – AsclepiX Therapeutics, Inc., a clinical stage biopharmaceutical company using computational...

Pharmaceutical Industry Veteran Further Strengthens the Executive Team BALTIMORE, MD, March 17, 2021 – AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular...

BALTIMORE, MD, January 5, 2021 – AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal...

BALTIMORE, MD, October 13, 2020 – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatmentof retinal and other...

Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing led by the Perceptive Xontogeny Venture Fund BALTIMORE, MD, June 24,...

Financing will advance clinical development of the Company’s lead product AXT107 BALTIMORE – AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide...